Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab, Ipilimumab, and SBRT in Salivary Gland Cancers
NCT03749460Phase 2Completed
- Sponsor
- University of Washington
- Start
- Jan 2019
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in salivary gland carcinoma (SGC), sponsored by University of Washington. Started Jan 2019; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT03749460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03749460.